

**List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse), 30.06.2018**

**Dated 9 January 2018**

**NOTIFICATION**

Sopharma AD notifies that for December 2017 the Company recorded an increase of sales revenues of 21% compared to the same month of 2016, including 73% increase of domestic sales and 4% increase of export sales.

For 2017, revenues from sales increased by 13% compared to 2016, including 3% increase of domestic sales and a 20% increase of export sales.

**Dated 11 January 2018**

**NOTIFICATION**

Sopharma AD plans to build the new lyophilic factory in Sofia in the first half of 2018. With the construction of the plant Sopharma AD will double the capacity of its current production facilities, which will ensure the production of sufficient quantities of the life-saving hospital product Methylprednisolone and will create additional workplaces. The built-up area will be about 3000 square meters, the building is planned to be two-storey and include both production and service spaces which are of particular importance for this highest-grade production because they provide the necessary purified water, humidity, purity, temperature and air pressure in the internal production environment, purified steam, etc. The whole project is expected to cost around 30 million leva.

**Dated 30 January 2018**

**NOTIFICATION**

Publication of the individual quarterly report for the fourth quarter of 2017 of Sopharma AD.

**Dated 30 January 2018**

**NOTIFICATION**

Sopharma AD received a notification for the sale of 250 000 shares, representing 0.19% of its capital, by CUPF Allianz Bulgaria. After the transaction the share of CUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.99%.

The date of the registration of the transaction with the Central Depository is 24 January 2018.

**Dated 30 January 2018**

### **NOTIFICATION**

Sopharma AD ended its most successful financial year after the crisis. 2017 ended with 12.5% revenue growth reaching 205.3 million BGN, 44.8% increase in operating profit, 30.7% EBITDA growth and almost 10% growth in net profit.

During this successful year, the company took two important investment decisions, namely to start the construction of:

1. An extraction plant in Kazanlak, which will allow more effective and modern production of all phyto products and

2. A new lyophilic plant in Sofia, a necessary step for increasing the production capacity for the life-saving Methylprednisolone.

After nearly five years of low investment activity these projects are a logical continuation of the company's sustainable development program and our well-recognized social function in the healthcare sector in Bulgaria.

**Dated 5 February 2018**

### **NOTIFICATION**

Sopharma AD notifies that for January 2018 the Company recorded an increase of sales revenues of 3% compared to the same month of 2017, including 5% increase of export sales and same level of domestic sales.

**Dated 8 February 2018**

### **NOTIFICATION**

Sopharma AD notifies that on 29 December 2017 the Company bought 1186 own shares representing 0.00088% of the share capital of the Company, at a total value of 5080.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 904 000, representing 6.61% of the share capital of the Company.

**Dated 23 February 2018**

### **NOTIFICATION**

Sopharma AD notifies that on 23.02.2018 an Extraordinary general meeting of shareholders took place.

The General meeting of shareholders approved the decision for transformation of Sopharma AD, UIC: 831902088 by merging Unipharm AD, UIC: 831537465 into it. As a result of the merger, the entire property of Unipharm AD, UIC: 831537465 will be transferred to Sopharma AD, UIC: 831902088 under the conditions of general succession.

The General meeting of shareholders approved the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger").

The General meeting of shareholders approved the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.

The General meeting of shareholders approved the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.

The General meeting of shareholders approved changes in the Company's Articles of Association which allows the payment of an interim dividend on the basis of a 6-month financial statement under the Public Offering of Securities Act.

The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approved a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition - no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share;

The minutes of the General Meeting of Shareholders of Sopharma AD, held on 23.02.2018, will be sent to you within the statutory term. All conversion documents are available as part of the materials of the extraordinary general meeting.

**Dated 23 February 2018**

### **NOTIFICATION**

Publishing the Minutes of the EGMS, held on 23.02.2018.

**Dated 1 March 2018**

## **NOTIFICATION**

Publication of quarterly consolidated statement for the fourth quarter of 2017 of Sopharma Group.

**Dated 1 March 2018**

## **NOTIFICATION**

Sopharma Group reported for the first time over BGN 1 billion in sales revenue for 2017, marking an increase of 15.9%. Over the same period, the Group achieved a 25.4% increase in operating profit, a 17.5% increase in EBITDA. Net profit declined by 16.1% due to the lack of one-off transactions that resulted in extremely high financial revenues as they were in 2016.

In the past year, a number of companies joined the Group, including Lekovit, Serbia and the pharmacies chain PharmaStore, Bulgaria. There is a process of integration of both structures and the achievement of synergy in all directions of the activity.

**Dated 6 March 2018**

## **NOTIFICATION**

Sopharma AD notifies that for February 2018 the Company recorded an increase of sales revenues of 2% compared to the same month of 2017, including 8% increase of domestic sales and same level of export sales.

For the first two months of this year, revenues from sales increased by 1% compared to the same period of 2017, including 2% increase of export sales and same level of domestic sales.

**Dated 30 March 2018**

## **NOTIFICATION**

Publication of the Annual Individual Report of Sopharma AD as at 31.12.2017.

**Dated 5 April 2018**

## **NOTIFICATION**

Sopharma AD notifies that for March 2018 the Company recorded a decrease of sales revenues of 10% compared to the same month of 2017, including 1% increase of domestic sales and a decrease of 19% of export sales.

For the first three months of this year, revenues from sales of products decreased by 3% compared to the same period of 2017, including 0.5% increase of domestic sales and 6% decrease of export sales.

**Dated 11 April 2018**

#### **NOTIFICATION**

Sopharma AD notifies that the filed on March 29, 2018 in the Commercial Register invitation for convening the Regular General Meeting of Shareholders of Sopharma AD on 11 May was not announced in accordance with the requirement of Art. 223, para 5 of the Commercial Law and the GMS cannot be conducted on this date.

The Board of Directors will propose another date for the GMS and will take the appropriate actions to convene it in the shortest possible time.

**Dated 27 April 2018**

#### **NOTIFICATION**

Publication of the Individual Financial Report of Sopharma AD for the three-month period ending 31.03.2018.

**Dated 27 April 2018**

#### **NOTIFICATION**

Publication of the Annual consolidated financial report of Sopharma AD for the period ending 31.12.2017.

**Dated 2 May 2018**

#### **NOTIFICATION**

Sopharma AD notifies that on April 30, 2018, the Registry Agency issued a refusal № 20180411164207 of the declared transformation of Unipharm AD into Sopharma AD under the Transformation Agreement of September, 14 2017 and the Additional Agreement of November, 8 2017.

The companies are considering to launch a new transformation procedure as soon as possible.

**Dated 3 May 2018**

**NOTIFICATION**

Publication of an invitation and materials for convening a GMS of Sopharma AD on 15.06.2018.

**Dated 9 May 2018**

**NOTIFICATION**

Sopharma AD notifies that for April 2018 the Company recorded an increase of sales revenues of 12% compared to the same month of 2017, including 1% increase of domestic sales and an increase of 21% of export sales.

For the first four months of this year, revenues from sales of products increased by 0,3% compared to the same period of 2017, including 0.5% increase of domestic sales and 0,1% increase of export sales.

**Dated 15 May 2018**

**NOTIFICATION**

Sopharma AD notifies that due to the refusal issued by the Registry agency for the registration of the transformation through merger of Unipharm AD into Sopharma AD that started in September 2017, the Board of directors of Sopharma AD took a decision to close the previous and start a new procedure for transformation of Sopharma AD under the conditions of Chapter XVI of the Commercial Law and Art. 122 and et seq of the Public Offering of Securities Law, to be implemented through the merger of Unipharm AD, UIC 831537465, with headquarters and address of management in Sofia, Studentski district, Darvenitsa, 3 Trayko Stanoev Str. into Sopharma AD. The Board of Directors of the Company elects the investment intermediary Elana Trading AD, UIC 831470130, with headquarters and address of management in Sofia, 5, Lachezar Stanchev Str., as consultant in connection with the implementation of the transformation procedure.

**Dated 30 May 2018**

**NOTIFICATION**

Publication of the Consolidated financial report of Sopharma AD for the three-month period ending 31.03.2018.

**Dated 1 June 2018**

### **NOTIFICATION**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2018	Buy	21	4,2200
01.06.2018	Buy	320	4,2200
01.06.2018	Buy	800	4,2300
01.06.2018	Buy	2 000	4,2100
01.06.2018	Buy	300	4,2400
01.06.2018	Buy	195	4,2400
01.06.2018	Buy	155	4,2100
01.06.2018	Buy	300	4,2300
01.06.2018	Buy	1 845	4,2100
01.06.2018	Buy	650	4,2200
01.06.2018	Buy	650	4,2200
01.06.2018	Buy	650	4,2200
01.06.2018	Buy	650	4,2200
01.06.2018	Buy	50	4,2200
01.06.2018	Buy	650	4,2200
01.06.2018	Buy	650	4,2200
01.06.2018	Buy	600	4,2200
01.06.2018	Buy	100	4,2200
01.06.2018	Buy	3 000	4,1700
01.06.2018	Buy	3 000	4,1700

**Dated 4 June 2018**

### **NOTIFICATION**

With deep sorrow we announce that Mr. Andrey Breshkov, a member of the Board of Directors of Sopharma AD, unexpectedly passed away. May he rest in peace!

Until the Company elects a Member of the Board of Directors in accordance with the Commercial Law and the Public Offering of Securities Act, the Board will continue to perform its functions with four members.

**Dated 5 June 2018**

### **NOTIFICATION**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
04.06.2018	Buy	2 000	4,2000
04.06.2018	Buy	5 000	4,2000
04.06.2018	Buy	2 000	4,1900
04.06.2018	Buy	3 000	4,1900
04.06.2018	Buy	5 000	4,1800

**Dated 5 June 2018**

### **NOTIFICATION**

Sopharma AD notifies that on 4 June 2018 the Company bought 6 600 own shares representing 0.00490% of the share capital of the Company, at a total value of 27900.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.23 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 040 766, representing 6.707% of the share capital of the Company.

**Dated 5 June 2018**

### **NOTIFICATION**

Sopharma AD notifies that for May 2018 the Company recorded a decrease of sales revenues of 11% compared to the same month of 2017, including 1% increase of domestic sales and a decrease of 16% of export sales.

For the first five months of this year, revenues from sales of products decreased by 2% compared to the same period of 2017, including 1% increase of domestic sales and 3% decrease of export sales.



**Dated 6 June 2018**

### **NOTIFICATION**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2018	Buy	50	4,1700

**Dated 7 June 2018**

### **NOTIFICATION**

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2018	Buy	1 000	4,24
01.06.2018	Buy	250	4,23
01.06.2018	Buy	1 000	4,24
01.06.2018	Buy	300	4,24
01.06.2018	Buy	200	4,24
01.06.2018	Buy	1 000	4,24
01.06.2018	Buy	5 000	4,24
04.06.2018	Buy	1000	4,23
04.06.2018	Buy	1000	4,23
04.06.2018	Buy	1000	4,23
04.06.2018	Buy	621	4,23
04.06.2018	Buy	1500	4,23
04.06.2018	Buy	1000	4,23
04.06.2018	Buy	1000	4,20
04.06.2018	Buy	1500	4,22
04.06.2018	Buy	1400	4,22
04.06.2018	Buy	1500	4,22
04.06.2018	Buy	4000	4,20

05.06.2018	Buy	100	4,23
05.06.2018	Buy	260	4,20

**Dated 7 June 2018**

### NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
06.06.2018	Buy	100	4,2100

**Dated 8 June 2018**

### NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
07.06.2018	Buy	2 000	4,2000
07.06.2018	Buy	717	4,2000
07.06.2018	Buy	1 283	4,2000
07.06.2018	Buy	17	4,2000
07.06.2018	Buy	983	4,2000
07.06.2018	Buy	506	4,2000
07.06.2018	Buy	494	4,2000
07.06.2018	Buy	501	4,2000
07.06.2018	Buy	399	4,2000
07.06.2018	Buy	100	4,2000
07.06.2018	Buy	264	4,2000
07.06.2018	Buy	1 300	4,2000
07.06.2018	Buy	300	4,2000
07.06.2018	Buy	200	4,2000

07.06.2018	Buy	5 000	4,2000
07.06.2018	Buy	200	4,2000
07.06.2018	Buy	2 000	4,2000
07.06.2018	Buy	2 500	4,2000
07.06.2018	Buy	500	4,2000
07.06.2018	Buy	2 500	4,2000
07.06.2018	Buy	2 500	4,2000
07.06.2018	Buy	1 000	4,2000
07.06.2018	Buy	1 000	4,2000
07.06.2018	Buy	1 000	4,2000
07.06.2018	Buy	1 000	4,2000
07.06.2018	Buy	1 000	4,2000
07.06.2018	Buy	1 000	4,2000
07.06.2018	Buy	500	4,2000
07.06.2018	Buy	1 500	4,2100
07.06.2018	Buy	273	4,2100
07.06.2018	Buy	200	4,2100
07.06.2018	Buy	1 500	4,2200
07.06.2018	Buy	2 000	4,2200
07.06.2018	Buy	27	4,2200
07.06.2018	Buy	1 497	4,2200
07.06.2018	Buy	503	4,2200
07.06.2018	Buy	1 500	4,2200
07.06.2018	Buy	497	4,2200
07.06.2018	Buy	3	4,2200

**Dated 8 June 2018**

### NOTIFICATION

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
07.06.2018	Buy	806	4,20
07.06.2018	Buy	194	4,20
07.06.2018	Buy	42	4,20
07.06.2018	Buy	300	4,20
07.06.2018	Buy	127	4,21
07.06.2018	Buy	100	4,21
07.06.2018	Buy	1003	4,22
07.06.2018	Buy	697	4,22

07.06.2018	Buy	1197	4,22
07.06.2018	Buy	803	4,22
07.06.2018	Buy	1500	4,22
07.06.2018	Buy	303	4,22
07.06.2018	Buy	197	4,22
07.06.2018	Buy	1303	4,22
07.06.2018	Buy	697	4,22
07.06.2018	Buy	500	4,22
07.06.2018	Buy	500	4,22
07.06.2018	Buy	500	4,22
07.06.2018	Buy	500	4,22

**Dated 11 June 2018**

### NOTIFICATION

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
08.06.2018	Buy	1 700	4,2200
08.06.2018	Buy	820	4,2200
08.06.2018	Buy	113	4,2200
08.06.2018	Buy	300	4,2200
08.06.2018	Buy	67	4,2200
08.06.2018	Buy	300	4,2100
08.06.2018	Buy	60	4,2100
08.06.2018	Buy	640	4,2200

**Dated 12 June 2018**

### NOTIFICATION

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
11.06.2018	Buy	1 360	4,2200
11.06.2018	Buy	400	4,2200
11.06.2018	Buy	1 240	4,2200
11.06.2018	Buy	1 000	4,2100
11.06.2018	Buy	850	4,2200
11.06.2018	Buy	150	4,2200

**Dated 13 June 2018**

### NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
12.06.2018	Buy	1 000	4,2200
12.06.2018	Buy	1 040	4,2200
12.06.2018	Buy	200	4,2200
12.06.2018	Buy	800	4,2300
12.06.2018	Buy	740	4,2300
12.06.2018	Buy	220	4,2300
12.06.2018	Buy	1 000	4,2400
12.06.2018	Buy	1 600	4,2400
12.06.2018	Buy	400	4,2400
12.06.2018	Buy	176	4,2300
12.06.2018	Buy	1 000	4,2400

**Dated 14 June 2018**

### NOTIFICATION

Sopharma AD hereby informs that on 13 June 2018 the Company bought 24 062 own shares representing 0.0179% of the share capital of the Company, at a total value of 102 654.12 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 064 828, representing 6.72% of the share capital of the Company.

**Dated 14 June 2018**

### NOTIFICATION

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
13.06.2018	Buy	112	4,2300
13.06.2018	Buy	383	4,2400
13.06.2018	Buy	329	4,2400
13.06.2018	Buy	500	4,2500
13.06.2018	Buy	300	4,2500
13.06.2018	Buy	300	4,2500
13.06.2018	Buy	300	4,2500
13.06.2018	Buy	256	4,2500
13.06.2018	Buy	344	4,2500
13.06.2018	Buy	300	4,2500
13.06.2018	Buy	300	4,2500
13.06.2018	Buy	250	4,2600
13.06.2018	Buy	1 150	4,2600
13.06.2018	Buy	1 150	4,2600
13.06.2018	Buy	2 350	4,2600
13.06.2018	Buy	500	4,2600
13.06.2018	Buy	520	4,2600
13.06.2018	Buy	230	4,2600
13.06.2018	Buy	250	4,2600
13.06.2018	Buy	350	4,2500
13.06.2018	Buy	450	4,2500
13.06.2018	Buy	1	4,2500
13.06.2018	Buy	199	4,2500
13.06.2018	Buy	1 955	4,2700
13.06.2018	Buy	45	4,2700
13.06.2018	Buy	1 000	4,2600
13.06.2018	Buy	450	4,2600
13.06.2018	Buy	450	4,2600
13.06.2018	Buy	81	4,2600
13.06.2018	Buy	19	4,2600
13.06.2018	Buy	126	4,2500

**Dated 14 June 2018**

## **NOTIFICATION**

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
11.06.2018	Buy	400	4,21
11.06.2018	Buy	100	4,23
12.06.2018	Buy	100	4,210
12.06.2018	Buy	400	4,220
12.06.2018	Buy	380	4,220
12.06.2018	Buy	620	4,22
12.06.2018	Buy	45	4,23
12.06.2018	Buy	936	4,23
12.06.2018	Buy	19	4,23
12.06.2018	Buy	836	4,23
12.06.2018	Buy	164	4,23
12.06.2018	Buy	200	4,23
12.06.2018	Buy	164	4,23
12.06.2018	Buy	1000	4,23
12.06.2018	Buy	1000	4,23
12.06.2018	Buy	1000	4,23
12.06.2018	Buy	856	4,23
12.06.2018	Buy	1600	4,24
12.06.2018	Buy	500	4,24
12.06.2018	Buy	190	4,24
12.06.2018	Buy	1600	4,24
12.06.2018	Buy	1600	4,24
12.06.2018	Buy	1600	4,24
12.06.2018	Buy	600	4,24
13.06.2018	Buy	44	4,25
13.06.2018	Buy	2	4,26
13.06.2018	Buy	450	4,26

**Dated 15 June 2018**

### **NOTIFICATION**

Sopharma AD notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 15, 2018 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:

AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.11 BGN /eleven stotinki/ per share with dividend right. The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken, namely June 29, 2018.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

**Dated 15 June 2018**

### **NOTIFICATION**

Sopharma AD notifies that on 14 June 2018 the Company bought 1 000 own shares representing 0.00074% of the share capital of the Company, at a total value of 4 260.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 065 828, representing 6.73% of the share capital of the Company.

**Dated 15 June 2018**

### **NOTIFICATION**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.06.2018	Buy	174	4,2700



14.06.2018	Buy	300	4,2600
14.06.2018	Buy	20	4,2600
14.06.2018	Buy	380	4,2600
14.06.2018	Buy	500	4,2700
14.06.2018	Buy	500	4,2600

**Dated 18 June 2018**

### NOTIFICATION

Sopharma AD notifies that on 15 June 2018 the Company bought 2 272 own shares representing 0.0017% of the share capital of the Company, at a total value of 9 652.72 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 068 100, representing 6.73% of the share capital of the Company.

**Dated 18 June 2018**

### NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
15.06.2018	Buy	1 000	4,2400
15.06.2018	Buy	500	4,2400
15.06.2018	Buy	500	4,2400
15.06.2018	Buy	180	4,2400
15.06.2018	Buy	300	4,2400
15.06.2018	Buy	520	4,2400
15.06.2018	Buy	400	4,2400

**Dated 19 June 2018**

## NOTIFICATION

Publication of the Minutes from the General Meeting of shareholders of Sopharma AD from 15.06.2018.

**Dated 19 June 2018**

## NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
18.06.2018	Buy	600	4,2600
18.06.2018	Buy	177	4,2300
18.06.2018	Buy	70	4,2300
18.06.2018	Buy	17	4,2300

**Dated 19 June 2018**

## NOTIFICATION

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
14.06.2018	Buy	480	4,26
18.06.2018	Buy	100	4,25
18.06.2018	Buy	100	4,25

**Dated 20 June 2018**

## NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transaction related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
19.06.2018	Buy	600	4,2300

**Dated 20 June 2018**

## NOTIFICATION

Sopharma AD notifies that on 19 June 2018 the Company bought 106 own shares representing 0.0000786% of the share capital of the Company, at a total value of 450.50 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 068 206, representing 6.73% of the share capital of the Company.

**Dated 21 June 2018**

## NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
20.06.2018	Buy	1 136	4,2500
20.06.2018	Buy	710	4,2400
20.06.2018	Buy	524	4,2300
20.06.2018	Buy	136	4,2300

**Dated 21 June 2018**

## NOTIFICATION

Sopharma AD notifies that on 20 June 2018 the Company bought 2 200 own shares representing 0.00163% of the share capital of the Company, at a total value of 9 340.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 070 406, representing 6.73% of the share capital of the Company.

**Dated 22 June 2018**

## NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
21.06.2018	Buy	630	4,2500
21.06.2018	Buy	1 000	4,2300
21.06.2018	Buy	162	4,2300
21.06.2018	Buy	400	4,2300

**Dated 22 June 2018**

## NOTIFICATION

Sopharma AD notifies that on 21 June 2018 the Company bought 4 250 own shares representing 0.0032% of the share capital of the Company, at a total value of 18 006.88 BGN on the Bulgarian Stock Exchange, the average price per share was 4.24 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 074 656, representing 6.73% of the share capital of the Company.

**Dated 25 June 2018**

## NOTIFICATION

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
22.06.2018	Buy	1 000	4,2200
22.06.2018	Buy	438	4,2400
22.06.2018	Buy	3 000	4,2300
22.06.2018	Buy	1 200	4,2200
22.06.2018	Buy	100	4,2400

**Dated 25 June 2018**

## NOTIFICATION

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
20.06.2018	Buy	300	4,23

**Dated 25 June 2018**

## NOTIFICATION

Sopharma AD notifies that on 22 June 2018 the Company bought 4 740 own shares representing 0.0035% of the share capital of the Company, at a total value of 20 002.80 BGN on the Bulgarian Stock Exchange, the average price per share was 4.22 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 079 396, representing 6.74% of the share capital of the Company.

**Dated 26 June 2018**

## NOTIFICATION

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
25.06.2018	Buy	3 500	4,2400
25.06.2018	Buy	300	4,2400
25.06.2018	Buy	300	4,2500
25.06.2018	Buy	1 500	4,2500
25.06.2018	Buy	34	4,2500
25.06.2018	Buy	310	4,2500
25.06.2018	Buy	1 500	4,2500
25.06.2018	Buy	1 500	4,2500
25.06.2018	Buy	500	4,2500
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	170	4,2600
25.06.2018	Buy	1 080	4,2600
25.06.2018	Buy	4 326	4,2600
25.06.2018	Buy	674	4,2600
25.06.2018	Buy	1 326	4,2600
25.06.2018	Buy	2 874	4,2600
25.06.2018	Buy	800	4,2600
25.06.2018	Buy	2 126	4,2600
25.06.2018	Buy	2 370	4,2600
25.06.2018	Buy	630	4,2600
25.06.2018	Buy	4 380	4,2600
25.06.2018	Buy	370	4,2600
25.06.2018	Buy	250	4,2600
25.06.2018	Buy	120	4,2600
25.06.2018	Buy	4 880	4,2600
25.06.2018	Buy	1 000	4,2600

25.06.2018	Buy	2 621	4,2700
25.06.2018	Buy	900	4,2700
25.06.2018	Buy	479	4,2700
25.06.2018	Buy	130	4,2700
25.06.2018	Buy	811	4,2900
25.06.2018	Buy	189	4,2900
25.06.2018	Buy	1 000	4,2700

**Dated 26 June 2018**

### **NOTIFICATION**

Sopharma AD notifies that on 25 June 2018 the Company bought 28 951 own shares representing 0.021% of the share capital of the Company, at a total value of 123 372.40 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 108 347, representing 6.76% of the share capital of the Company.

**Dated 27 June 2018**

### **NOTIFICATION**

Sopharma AD notifies that on 25 June 2018 Sopharma AD received an approval from the FSC of the Contract for transformation through merger of Unipharm AD in Sopharma AD and reports of the boards of directors and the independent evaluators. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.957502, meaning that one share of Unipharm AD will be exchanged for 0.957502 shares of Sopharma AD from the treasury shares available to the receiving company.

The terms and conditions of the merger are available in detail in the Contract for transformation through merger and the reports of the boards of directors and the independent evaluators which are subject to approval by the general meetings of shareholders of both companies. The procedures for convening general meetings for both companies will be initiated on 1 August 2018.

**Dated 27 June 2018**

## NOTIFICATION

Sopharma AD notifies that on 26 June 2018 the Company bought 19 373 own shares representing 0.0144% of the share capital of the Company, at a total value of 82 568.31 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 127 720, representing 6.77% of the share capital of the Company.

**Dated 27 June 2018**

## NOTIFICATION

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
25.06.2018	Buy	970	4,26
25.06.2018	Buy	910	4,26
25.06.2018	Buy	120	4,26
25.06.2018	Buy	500	4,26
25.06.2018	Buy	530	4,26
25.06.2018	Buy	879	4,27
25.06.2018	Buy	4121	4,27
25.06.2018	Buy	2479	4,27
25.06.2018	Buy	2000	4,27
25.06.2018	Buy	521	4,27
25.06.2018	Buy	5000	4,27
25.06.2018	Buy	2134	4,27
25.06.2018	Buy	2866	4,27
25.06.2018	Buy	366	4,27
25.06.2018	Buy	2500	4,28
25.06.2018	Buy	2634	4,27
25.06.2018	Buy	2366	4,27
25.06.2018	Buy	5000	4,27
25.06.2018	Buy	3000	4,27
25.06.2018	Buy	1710	4,27
25.06.2018	Buy	290	4,27
25.06.2018	Buy	1810	4,27
25.06.2018	Buy	190	4,27



25.06.2018	Buy	2018	4,27
25.06.2018	Buy	200	4,28
25.06.2018	Buy	2800	4,28
25.06.2018	Buy	1200	4,27
25.06.2018	Buy	1200	4,27
25.06.2018	Buy	1200	4,27
25.06.2018	Buy	1200	4,27
25.06.2018	Buy	952	4,27
25.06.2018	Buy	1448	4,27
25.06.2018	Buy	3000	4,27
25.06.2018	Buy	552	4,27
25.06.2018	Buy	300	4,29
25.06.2018	Buy	200	4,29
26.06.2018	Buy	600	4,27
26.06.2018	Buy	200	4,29
26.06.2018	Buy	1000	4,27
26.06.2018	Buy	77	4,27
26.06.2018	Buy	73	4,27
26.06.2018	Buy	3027	4,27
26.06.2018	Buy	2000	4,27
26.06.2018	Buy	200	4,26
26.06.2018	Buy	600	4,26
26.06.2018	Buy	600	4,26
26.06.2018	Buy	600	4,26
26.06.2018	Buy	471	4,26
26.06.2018	Buy	500	4,25

**Dated 28 June 2018**

#### **NOTIFICATION**

Sopharma AD notifies that on 27 June 2018 the Company bought 11857 own shares representing 0.0088% of the share capital of the Company, at a total value of 50 273.68 BGN on the Bulgarian Stock Exchange, the average price per share was 4.24 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 139 577, representing 6.78% of the share capital of the Company.

**Dated 29 June 2018**

#### **NOTIFICATION**

Sopharma AD notifies that on 28 June 2018 the Company bought 233 own shares representing 0.00017% of the share capital of the Company, at a total value of 959.96 BGN on the Bulgarian Stock Exchange, the average price per share was 4.12 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 139 810, representing 6.78% of the share capital of the Company.

**Dated 29 June 2018**

## **NOTIFICATION**

Publication of an invitation and materials for convening an Extraordinary General meeting of shareholders of Sopharma AD scheduled for 1 August 2018.